Imfinzi approved in the US for endometrial cancer
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Accelerating sustainability in Indian pharma industry
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Subscribe To Our Newsletter & Stay Updated